- Home
- CANF vs SYM Comparison
CANF vs SYM Comparison
Compare CANF & SYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- SYM
- Stock Information
- Founded
- CANF 1994
- SYM 2005
- Country
- CANF Israel
- SYM United States
- Employees
- CANF N/A
- SYM N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- SYM Industrial Machinery/Components
- Sector
- CANF Health Care
- SYM Industrials
- Exchange
- CANF Nasdaq
- SYM Nasdaq
- Market Cap
- CANF 7.9M
- SYM N/A
- IPO Year
- CANF N/A
- SYM N/A
- Fundamental
- Price
- CANF $1.12
- SYM $23.94
- Analyst Decision
- CANF Strong Buy
- SYM Buy
- Analyst Count
- CANF 2
- SYM 17
- Target Price
- CANF $14.00
- SYM $38.60
- AVG Volume (30 Days)
- CANF 444.9K
- SYM 981.8K
- Earning Date
- CANF 05-20-2025
- SYM 05-07-2025
- Dividend Yield
- CANF N/A
- SYM N/A
- EPS Growth
- CANF N/A
- SYM N/A
- EPS
- CANF N/A
- SYM N/A
- Revenue
- CANF $674,000.00
- SYM $2,071,248,000.00
- Revenue This Year
- CANF $461.72
- SYM $27.34
- Revenue Next Year
- CANF N/A
- SYM $32.50
- P/E Ratio
- CANF N/A
- SYM N/A
- Revenue Growth
- CANF N/A
- SYM 42.16
- 52 Week Low
- CANF $1.02
- SYM $16.32
- 52 Week High
- CANF $4.69
- SYM $47.88
- Technical
- Relative Strength Index (RSI)
- CANF 40.25
- SYM 61.94
- Support Level
- CANF $1.02
- SYM $21.89
- Resistance Level
- CANF $1.20
- SYM $23.63
- Average True Range (ATR)
- CANF 0.06
- SYM 1.07
- MACD
- CANF 0.01
- SYM 0.32
- Stochastic Oscillator
- CANF 41.30
- SYM 76.49
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).